Biblio
Found 39 results
Filters: Author is Huang, D. [Clear All Filters]
The catalytic mechanism of the RNA methyltransferase METTL3. eLife. 12:RP92537.
.
2024. Rapid ex vivo reverse genetics identifies the essential determinants of prion protein toxicity. Brain Pathology. 33(2):e13130.
.
2023. Structure-Based Design of inhibitors of the m6A‑RNA writer enzyme METTL3. ACS Bio & Med Chem Au. 3(4):359–370.
.
2023. Structure-based design of ligands of the m6A-RNA reader YTHDC1. European Journal of Medicinal Chemistry Reports. 5:100057.
.
2022. 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. Journal of Medicinal Chemistry. 64(17):12738-12760.
.
2021. Atomistic and thermodynamic analysis of N6-methyladenosine (mA) recognition by the reader domain of YTHDC1. Journal of Chemical Theory and Computation. 17(2):1240-1249.
.
2021. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem. 16(19):3035-3043.
.
2021. Hitting a moving target: simulation and crystallography study of ATAD2 bromodomain blockers. ACS Medicinal Chemistry Letters. 11(8):1573-1580.
.
2020. Selectively disrupting m6A-dependent protein-RNA interactions with fragments. ACS Chemical Biology. 15(3):618-625.
.
2020. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem. 15(9):744-748.
.
2020. Flexible binding of m6A reader protein YTHDC1 to its preferred RNA motif. Journal of Chemical Theory and Computation. 15(12):7004-7014.
.
2019. Evolutionary conserved Tyr169 stabilizes the β2-α2 loop of the prion protein. Journal of the American Chemical Society. 137(8):2948-2957.
.
2015. The roles of the conserved tyrosine in the β2-α2 loop of the prion protein. Prion. 9(6):412-419.
.
2015. Structural analysis of the binding of type I, I1/2, and II inhibitors to eph tyrosine kinases. ACS Medicinal Chemistry Letters. 6(1):79-83.
.
2015. Structure-based drug design identifies polythiophenes as antiprion compounds. Science Translational Medicine. 7(299):299ra123.
.
2015. Structured water molecules in the binding site of bromodomains can be displaced by cosolvent. ChemMedChem. 9(3):573-579.
.
2014. Does bromodomain flexibility influence histone recognition? FEBS Letters. 587(14):2158-2163.
.
2013. Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography. Journal of Medicinal Chemistry. 56(1):84-96.
.
2013. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics. ChemMedChem. 7(11):1983-1990.
.
2012. How does Darunavir prevent HIV-1 protease dimerization? Journal of Chemical Theory and Computation. 8(5):1786-1794.
.
2012. The free energy landscape of small molecule unbinding. PLoS Computational Biology. 7(2):e1002002.
.
2011. Hydrogen bonding penalty upon ligand binding. PLoS One. 6(6):e19923.
.
2011. Small molecule binding to proteins: Affinity and binding/unbinding dynamics from atomistic simulations. ChemMedChem. 6(9):1578-80.
.
2011. Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis. Bioinformatics. 26(2):198-204.
.
2010. Library screening by fragment-based docking. Journal of Molecular Recognition. 23(2):183-193.
.
2010.